Video

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

Author(s):

Jarushka Naidoo, MD, M.B.B.Ch.Solange Peters, MD, PhD

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Sponsored in part by Regeneron. Content independently created by OncLive.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Related Content
Luis G. Paz-Ares, MD, PhD, chair, Medical Oncology Department, Hospital Universitario 12 de Octubre; associate professor, Universidad Complutense de Madrid
June 11th 2024

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
June 10th 2024

FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Lung cancer - stock.adobe.com
June 4th 2024

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

David Planchard, MD, PhD
June 4th 2024

Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC